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COPD remains a major cause of mortality and morbidity across the world. The World
Health Organization listed COPD as the fourth leading cause of death worldwide
(alongside lower respiratory infections) in 2015, resulting in an estimated 3.17 million
deaths that year.1
Acute exacerbations of COPD (AECOPD) carry a poor prognosis with a calculated
1- and 2-year mortality of 22% and 36%, respectively.2,3 Patients with frequent exacerbations have more than 4 times risk of death compared with non-exacerbators.4
There is increasing focus in medical literature on COPD comorbidities.5–8 The
Global Initiative for Chronic Obstructive Lung Disease guidelines (2016) dedicate
a full chapter to the management of comorbidities in COPD, emphasizing their
importance.7 COPD patients are at higher risk of CVS disease. CVS disease is
associated with high morbidity and mortality in COPD patients.8–10 The ECLIPSE
group showed that CVS disease was an independent risk factor for mortality after
adjusting for age, gender and smoking history in their cohort of 2,164 patients.9 The
estimated mortality hazard ratio of having concurrent heart failure (HF) in COPD
patients compared with those without HF is 1.3–1.9; concurrent ischemic heart disease
(IHD) has a hazard ratio of 1.27–1.5; and concurrent atrial fibrillation/flutter has a
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Background: Cardiovascular (CVS) comorbidities are common in COPD and contribute
significantly to morbidity and mortality, especially following acute exacerbations of COPD
(AECOPD). Beta-blockers (BBs) are safe and effective in COPD patients, with demonstrated
survival benefit following myocardial infarction. We sought to determine if BBs are underprescribed in patients hospitalized with AECOPD. We also sought to determine inpatient rates
of CVS and cerebrovascular complications, and their impact on patient outcomes.
Methods: Retrospective hospital data was collected over a 12-month period. The medical
records of all patients 40 years of age coded with a diagnosis of AECOPD were analyzed.
Prevalent use and incident initiation of BBs were assessed. Comorbidities including indications
and contraindications for BB use were analyzed.
Results: Of the 366 eligible patients, 156 patients (42.6%) had at least one indication for BB
use – of these patients, only 53 (34.0%) were on BB therapy and 61 (39.1%) were not on BB
therapy but had no listed contraindication. Prevalent use of BBs at the time of admission in all
366 patients was 19.7%, compared with 45.6%, 39.6% and 45.9% use of anti-platelets, statins
and angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, respectively. CVS
and cerebrovascular complications were common in this population (57 patients, 16%) and were
associated with longer length of stay (p,0.01) and greater inpatient mortality (p=0.02).
Conclusions: BBs are under-prescribed in COPD patients despite clear indication(s) for their
use. Further work is required to explore barriers to BB prescribing in COPD patients.
Keywords: COPD exacerbations, beta-blockers, cardiovascular, comorbidity
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hazard ratio of 1.56.8–10 The optimum management of CVS
comorbidities in COPD has not been fully ascertained.
Beta-blockers (BBs) have proven mortality benefit in
patients with IHD and HF.11–14 Subgroup analysis of postmyocardial infarction (post-MI) patients has shown a consistent beneficial effect in patients with concurrent COPD.11,12
Registry data also points to improved survival in post-MI
COPD patients initiated early on beta-blockade therapy.15
There may even be beneficial effects of BBs in COPD patients
independent from CVS effects. Indeed, in a Scottish retrospective cohort study conducted in 2011 by Short et al using
the TARDIS database, use of BBs was associated with 22%
reduction in all-cause mortality as well as reduction in need of
emergency oral corticosteroid use and hospital admissions.16
There has previously been debate about the safety of
BBs in patients with COPD. A Cochrane meta-analysis conducted in 2011 demonstrated the safety of BB use in COPD,
showing no significant change in forced expiratory volume
in 1 s (FEV1), respiratory symptoms or FEV1 response to
bronchodilators when compared with placebo.17 This includes
COPD patients with FEV1 ,50% predicted or 1.4 L and
those with reversible airflow limitation. Nevertheless, there
remains a persisting reluctance from physicians to prescribe
BBs in COPD patients primarily because of the perceived
risk of inducing bronchospasm.

Aims
In order to determine local prescribing practices of BBs,
we examined hospital inpatients at a major tertiary hospital
admitted with an AECOPD. The primary aim of the study
was to measure prevalent rates at time of hospitalization of
appropriate BB use in this group of COPD patients. We also
sought to determine the rates of CVS and cerebrovascular
(CVA) events during acute COPD exacerbation admissions,
and examined their impact on hospital length of stay, intensive care unit (ICU) admissions and in-patient mortality.

Methods
We conducted a retrospective cohort study on patients .40
years of age admitted with AECOPD over 1 year (1 January
2012 to 31 December 2012) in a large tertiary metropolitan
hospital. For patients with repeat admissions during the
year, only the first admission was included in the analysis.
Data was collected from hospital electronic databases and
discharge summaries.
Appropriate use of BBs was defined as having at least
1 indication for use in the absence of contraindications.
We defined indications for BB therapy as having a history of
IHD, congestive cardiac failure (CCF) and tachyarrhythmias.
3042
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Contraindications included a history of BB allergy, bradyarrhythmias, asthma, peripheral vascular disease and
hypotension.
IHD events included any of the following: ST-elevation
MI, non-ST elevation MI, unstable angina or stable angina.
CVA events included ischemic stroke, hemorrhagic stroke
and transient ischemic attack.
This project was approved by the Royal Perth Hospital
Human Research Ethics Committee (EC00270/HREC REG
14–045). The Committee approved waiver of patient consent,
as this was classified a negligible-risk study. De-identified
data was used throughout the study.
Statistical analysis was performed on Stata® software.
Student’s independent t-test, Chi square and Fisher’s exact
tests were used for inter-group comparisons with an alphaerror cutoff of 0.05.

Results
A total of 572 admissions were retrieved on initial clinical
coding screen. 366 patients were included in the data analysis
(Figure 1). The basic patient demographics and clinical outcomes are shown in Table 1.

Prevalence of appropriate use of BBs at
the time of admission
The prevalence of BB use on admission was 19.7% (72 of
366). Of all patients, 42.6% (156 of 366) had at least 1 indication for BB use. Of these patients, 34.0% (53 of 156) were
on BBs, 39.1% (61) were not on BBs and had no known
contraindications for their use, and 26.9% (42) were not on
BBs and had known potential contraindications (Figure 1).
The breakdowns of the indications and contraindications to
BB use are listed in Table 2.

Cardioselective and non-cardioselective
BBs
Sixty-two out of the 72 (86.1%) patients on BB therapy at the
time of admission were on cardioselective BBs (metoprolol
28, bisoprolol 18, atenolol 11, nebivolol 5). The 8 patients
who were initiated on BB therapy during their admission were
all commenced on cardioselective BBs (metoprolol 8).
Table 1 Patient demographics and clinical outcomes
Number of males/females: 208/158 (ratio 1.3:1)
Mean age: 72.7 years (±12.1 SD)
Mean length of stay: 5.1 days (±5.5 SD)
Median length of stay: 3 days (interquartile range =2–6)
Number of ICU admissions: 7 (1.9%)
Number of deaths: 11 (3.0%)
Abbreviation: ICU, intensive care unit.
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Figure 1 CONSORT diagram.
Note: Text/data shown in bold are the important points.
Abbreviation: BB, beta-blocker.

Inter-group analyses
We performed inter-group outcome analyses to detect trends.
It is important to note that these analyses were not adjusted
for confounders and the study was not powered to detect
outcome differences.
We compared the outcomes between AECOPD patients on
BB therapy on admission (n=72) and patients not on BB therapy
on admission (n=294). There were more in-hospital incident
CCF events in the on-therapy group (p,0.01) compared with
the off-therapy group. However, patients in the on-therapy
group were also more likely to have a history of HF (p,0.01)
or IHD (p,0.01). There were no statistically significant differences in length of stay, mortality, intensive care admissions, or
in-hospital incident tachyarrhythmia, IHD or CVA events.
We then compared the outcomes between AECOPD
patients with at least 1 indication for BB use and were appropriately on BB (n=53), and patients with at least 1 indication
Table 2 Indications and contraindications for beta-blocker use

and no contraindication but were inappropriately not on
BB (n=61). In the mortality analysis, there were fewer deaths
in the appropriately treated group (0 out of 53) compared
with the group that were inappropriately not on BB therapy
(6 out of 61), but this did not reach statistical significance
(p=0.063 by Fisher’s exact test). There were no statistically
significant differences in length of stay, or in-hospital incident tachyarrhythmia, IHD, CCF or CVA events.

CVS drug prescribing patterns
We compared the prescribing practices of BBs compared
with other CVS drugs. 19.7% of patients with AECOPD
were prescribed BBs, while 45.6% were on anti-platelet
medications, 39.6% on statins and 45.9% on angiotensinconverting enzyme inhibitor/angiotensin II receptor blockers
(ACEi/ARBs) (Table 3). In patients with a documented

Table 3 Prevalent use of cardiovascular drugs in AECOPD patients

Percentage of
patients, % (n=366)
Indications
Ischemic heart disease
Congestive cardiac failure
Tachyarrhythmias
At least 1 indication
More than 1 indication

33.1 (121)
15.8 (58)
11.2 (41)
42.6 (156)
15.0 (55)

Contraindications
Beta-blocker allergy
Asthma
Peripheral vascular disease
Bradyarrhythmias
Hypotension
At least 1 contraindication

0.3 (1)
17.8 (65)
5.7 (21)
7.7 (28)
3.0 (11)
31.7 (116)

Note: Values shown in bold are the important points.
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% baseline use
in all AECOPD
patients (n=366)
% prevalent use
in patients with
incident IHD
events (n=25)
% prevalent use
in patients with
previous history
of IHD (n=16)

Betablocker, %

Anti-platelet
drug, %

Statin, %

ACEi/
ARB, %

19.7

45.6

39.6

45.9

16

48

44

44

25

75

68.8

68.8

Abbreviations: ACEi, angiotensin converting enzyme inhibitor; AECOPD, acute
exacerbation of chronic obstructive pulmonary disease; ARB, angiotensin II receptor
blocker; IHD, ischemic heart disease.
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Table 4 Initiation of cardiovascular drugs in AECOPD patients
with new IHD events
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n=25

BetaAnti-platelet Statin
blocker drug

% incident initiation of 14.3%
76.9%
therapy in treatment- (3 of 21) (10 of 13)
naïve patients

ACEi/ARB

28.6%
14.3%
(4 of 14) (2 of 14)

Abbreviations: ACEi, angiotensin converting enzyme inhibitor; AECOPD, acute
exacerbation of chronic obstructive pulmonary disease; ARB, angiotensin II receptor
blocker; IHD, ischemic heart disease.

history of IHD, the prevalence of BB use was 25%, compared with 75% anti-platelet use, 68.8% statin use and 68.8%
ACEi/ARB use.

Patients with incident IHD events during
admission
Twenty-five out of 366 patients (6.8%) had an incident IHD
event during their inpatient stay. Sixteen of the 25 patients
(64%) had a prior history of IHD; however, only 4 out of the
25 patients (16%) were on BB therapy. In treatment-naïve
patients with new IHD events, 14.3% were commenced on a
BB during the admission, compared with 76.9% commenced
on anti-platelet therapy (Table 4).

CVS and CVA events
CVS and CVA events occurred frequently in our cohort of
AECOPD patients. Fifty-seven out of 366 patients (15.6%)
S
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Figure 2 Clinical endpoints for AECOPD patients stratified by incidence of
cardiovascular or cerebrovascular events.
Abbreviations: AECOPD, acute exacerbation of chronic obstructive pulmonary
disease; CVS, cardiovascular; CVA, cerebrovascular; ICU, intensive care unit.
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had CVS and/or CVA events during their admission. A total
of 70 CVS/CVA events were identified: CCF exacerbations
were the most common (27), followed by IHD events (25),
tachyarrhythmias (16) and strokes (2).
In-hospital CVS/CVA events were associated with a
longer mean hospital length of stay (7.3 days vs 4.7 days,
p,0.01) and a higher inpatient mortality (8.8% vs 1.9%,
p=0.02; Figure 2). A greater percentage of patients with
CVS/CVA events had ICU admissions (5.2% vs 1.3%,
p=0.13), but this was not statistically significant.

Discussion
Our results show that BBs are under used in patients
admitted with AECOPD despite indication(s) for their use.
Some of these patients had significant cardiac histories
with no contraindication for use. This highlights a disparity
between the existing evidence base and routine clinical practice, which may be detrimental to the care of this high-risk
group of patients.
Our results complement those described by Neef et al in a
separate Australian state, which showed only 51% of patients
with a history of heart failure with reduced ejection fraction
and COPD, and 31% of patients with a history of previous
MI and COPD, were on BBs at the time of admission.18
The prevalent use of CVS drugs were comparable with
the UK EXODUS cohort reported by Harrison et al – 17%
of patients were on BBs at baseline, 42% statins, 50% ACEi/
ARBs, 46% aspirin and 7% clopidogrel in the EXODUS
cohort (n=1,343) compared with 20% BBs, 40% statins,
46% ACEi/ARBs and 46% anti-platelets (any) in our cohort
(n=366).19 This indicates that BB under-prescribing is not an
isolated problem and perhaps reflects physicians’ persistent
hesitancy in prescribing BBs in COPD patients.
Furthermore, our data shows that the under-use of BB
therapy holds true in patients with new cardiac events during
their admission for AECOPD. BBs are poorly prescribed
compared with other CVS drug classes, suggesting ongoing
hesitancy regarding safety of initiation in COPD patients.
A COPD patient suffering an inpatient IHD event is 5.5 times
more likely to be started on an anti-platelet agent than a BB.
This shows a deviation from evidence-based practice.
Our cohort had a high prevalence (~1 in 6) of CVS or CVA
events during their admission and this resulted in increased
mortality and length of stay. These findings are consistent
with previous studies, which also indicate a startlingly high
frequency of these events.6–10 Donaldson et al report incidence
rates of 1.1 MIs per 100 patient-years and 1.4 stroke per
100 patient-years in a cohort of 25,857 COPD exacerbation
patients.20 Cause-specific mortality analysis of the TORCH
International Journal of COPD 2017:12
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study cohort indicated that 27% of the 911 deaths were attributed to CVS causes.21 Indeed, it has been shown that cardiac
dysfunction during COPD exacerbations and arrhythmogenic
sympathetic activation may be major contributors to morbidity
and should be viewed as an important therapeutic targets.22,23
There is some evidence from observational data that
BBs in COPD may reduce all-cause mortality or at least
improve outcomes, including exacerbation frequency.13–18,24,25
Perhaps there is a role for BBs in all COPD patients. There
is an ongoing prospective multi-center, double-blinded,
placebo-controlled randomized trial (βLOCK COPD) recruiting moderate-to-severe COPD patients with no absolute
indication for BB therapy to treatment with metoprolol vs
placebo with the primary outcome measure being time to
first exacerbation of COPD (secondary outcomes include
frequency of exacerbations and mortality).26
The management of COPD comorbidities is vital in the
overall optimal treatment algorithm of the disease. Safe and
effective use of cardioselective BBs in COPD patients is
likely going to be an important piece of the puzzle. The correct choice of BB is likely to be crucial.27–29 There may also
be a subset of severely unwell patients in whom BB initiation
carries higher risk of morbidity.29,30

Limitations
We accept that there are limitations to this study. First,
this is a retrospective study looking primarily at electronic
discharge summaries and medication prescriptions. Second,
the diagnoses labeled were clinical or historical. We did not
have full data on spirometric diagnosis of COPD nor did we
have echocardiogram reports on severity of left ventricular
dysfunction. Third, our definitions on contraindications were
intentionally broad. While this may overestimate the true
prevalence of contraindications to BBs, it was intentional so
that any bias would be toward the null hypothesis. Finally,
we also intentionally excluded hypertension as an indication
for BB therapy so as not to overestimate the under-utilization
of BBs. Although BBs are often used for this indication,
there are other classes of medication that may be used in
its place.
Our data adds to evidence of BB under-prescribing in
this high-risk population of patients. It indicates the need to
review prescribing practices in COPD patients with cardiac
comorbidities. We suggest: 1) Regular audit of BB and
CVS drugs prescribing practices in COPD patients in both
inpatient and outpatient settings. 2) Education across other
medical specialties about the safety and potential benefits
of BBs in COPD patients. 3) Safety and governance review
of BB-associated morbidity in COPD patients to identify
International Journal of COPD 2017:12
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potential subgroups who may not be suitable for this line
of treatment. 4) Collaborative research toward defining the
optimal place of BB therapy in COPD management. This
should include studies on secondary and tertiary prevention
of comorbid CVS events, longitudinal cohort studies to assess
long-term safety profiles of therapy, and intervention trials
with relevant clinical outcomes like mortality, exacerbation
frequency, rate of lung function decline and CVS or nonCVS morbidity.
The take-away message is: if a COPD patient has an
absolute indication for BB use (and no contraindication),
consider prescribing one.
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